Beta-Lactams

Precision dosing for beta-lactam therapy.

Beta-lactams are first-line for most serious infections, yet a standard dose leaves many acutely ill patients below their pharmacodynamic target. These modules support individualized dosing for the agents where reaching that target matters most.

InsightRX helps clinicians dose beta-lactams in line with the 2026 multisociety consensus guidance, endorsed by IDSA, ACCP, SCCM, and ESCMID, on dose individualization in acutely ill patients. Read more below.

  1. Home
  2. MIPD for Providers
  3. Drug Modules for Provider MIPD Applications
  4. Beta-lactam

The problem: why a standard dose is not a reliable dose

Most beta-lactam dosing still relies on a one-size-fits-all approach, scaled to body weight or estimated kidney function. In acutely ill patients, that breaks down. Critical illness alters the two pharmacokinetic parameters that matter most, the clearance (CL) and the volume of distribution (Vd) of these drugs, through many overlapping mechanisms at once.

This variability is why individualized dosing is gaining formal support. In one prospective study of critically ill patients, a model-based dosing tool demonstrated a dose different from the standard label in roughly one in five cases (Heil et al., 2018).

And in 2026, a multisociety consensus guidance endorsed by IDSA, ACCP, SCCM, and ESCMID suggested beta-lactam dose individualization to improve patient-centered outcomes, citing a meta-analysis in which it was associated with nearly twice the odds of clinical cure.

Predominant PK effect shown. Most populations affect both to some degree.
Augmented renal clearance
Fast elimination drives concentrations below target.
CL
Renal replacement therapy
Extracorporeal circuits change drug removal.
CL
Kidney dysfunction
Slowed elimination risks accumulation.
CL
Sepsis & septic shock
Capillary leak expands the distribution space.
Vd
Extremes of body weight
Body habitus shifts the volume of distribution.
Vd
Hypoalbuminemia
A higher unbound fraction shifts both parameters.
CLVd

The solution: Bayesian MIPD

A dosing table sorts patients into bands. It asks whether estimated kidney function sits above or below a threshold and applies the same regimen to everyone on the same side of the line. It cannot ask where inside that band a particular patient falls, or what exposure that patient will actually reach.

Which regimen would you choose?

Against an organism at an MIC of 8 mg/L, the useful cefepime trough is narrow at both ends. The 2026 consensus guidance sets a minimum target of 100% fT>MIC, which means holding the trough at or above the MIC, and notes that cefepime neurotoxicity risk rises at troughs above 20–35 mg/L (Barreto et al., Pharmacotherapy, 2026). Taking the cautious end of that range leaves a window of roughly 8–20 mg/L, about 2.5-fold, and a dosing table has no way to aim at it.

72-year-old female
Weight
55 kg
Serum creatinine
0.6 mg/dL
Estimated CrCl
74 mL/min
Target trough
8–20 mg/L
Hospital-acquired pneumonia, day 2. Pseudomonas aeruginosa, cefepime MIC 8 mg/L. No prior kidney disease. Frail, low muscle mass.
Select a regimen
Every regimen gives the first dose over 30 minutes, then maintenance as a 3-hour infusion; four doses shown. Illustrative simulation only.
Select a regimen to see the exposure this patient would be estimated to reach.

What a dosing table cannot see

The patient's estimated clearance is 74 mL/min. Most hospital nomograms begin adjusting at 60, so the patient is never flagged for a reduction at all. The estimate is not wrong, only too coarse to say where inside that band a 55 kg, 72-year-old patient will land.

Model-informed precision dosing runs before the first dose. MIPD platforms like InsightRX Nova read age, weight, sex and creatinine together, in the continuous relationships those covariates actually hold, and project what each candidate regimen would produce for this patient rather than for a generic patient's band.

Where each trough is predicted to land

Module bundle features and benefits

Modules included in this bundle
  • Cefepime
  • Meropenem
  • Piperacillin
  • Piperacillin-tazobactam
  • Amoxicillin
  • Ceftriaxone
  • Ceftazidime
Each module runs on population PK models reviewed and validated by experts in data science and pharmacometrics before deployment.
Infusion strategy support
Model intermittent, extended, and continuous infusions to keep free concentrations above the MIC across the interval.
Reach clinical targets from the beginning
Start from a model-based estimate of each patient's exposure, giving clinical teams the tools to assess target early rather than after days of adjustment.
Stewardship program analytics
Apollo helps teams track beta-lactam target attainment across antimicrobial stewardship programs, giving a clear view of performance and where to focus.
Adapt to shifting physiology
Account for the fast-clearing, fluid-shifted physiology of acutely ill patients that standard dosing misses.

A multisociety consensus on individualized dosing

In 2026, seven professional societies published consensus guidance on beta-lactam dose individualization in acutely ill patients (Barreto et al., Pharmacotherapy, 2026). In the panel's meta-analysis, dose regimen individualization was associated with nearly twice the odds of clinical cure (odds ratio 1.99, 95% CI 1.54 to 2.56).

On patient populations:

The guidance identifies the acutely ill populations where individualization matters most. Unstable pharmacokinetics is the common thread: critical illness, organ support, and shifting kidney function all pull drug concentrations away from what a standard dose predicts.

Section 3.5.1
The panel supports the use of beta-lactam dose individualization in patients with critical illness (e.g., intensive care unit, sepsis, septic shock), use of extracorporeal devices including extracorporeal membrane oxygenation, kidney replacement therapy, plasmapheresis, and blood purification/adsorptive systems (e.g., hemoadsorption) and/or in patients with kidney dysfunction (e.g., acute kidney injury, chronic kidney disease) or augmented renal clearance.

On implementation:

Many health systems already run Bayesian dosing programs for vancomycin. The panel supports building beta-lactam programs the same way, with iterative evaluation once a program is in place.

Section 4.2.1
The panel supports patterning beta-lactam dose individualization workflows after those of other antibiotics such as vancomycin.

On methodology:

The panel draws a clear distinction on method. Proactive model-informed precision dosing anticipates a patient's exposure from the first dose rather than reacting to a level after the fact, and the guidance favors it over traditional therapeutic drug monitoring.

Section 5.1.1
The panel supports the use of proactive MIPD with beta-lactam concentrations over traditional TDM, the latter of which is reactive.

These statements are drawn from the 2026 multisociety consensus guidance. Read the full guidance in Pharmacotherapy.

Maximize therapeutic success
with precision medicine.

Contact Us